Correlation of serum TNF-α, IL-4 and sIL-2R levels with radiologic and clinical manifestations in active pulmonary tuberculosis Source: Eur Respir J 2003; 22: Suppl. 45, 339s Year: 2003
Evaluation of sICAM-1 as a serum marker for follow-up of pulmonary tuberculosis therapy Source: Eur Respir J 2005; 26: Suppl. 49, 454s Year: 2005
TNF-alpha, IL-8, IL-6 levels in serum of sarcoidosis patients with different clinical course Source: Annual Congress 2013 –Sarcoidosis and other granulomatosis Year: 2013
Serum interleukin 6 levels predict disease progression in scleroderma-associated interstitial lung disease Source: Annual Congress 2010 - Biomarkers in diffuse parenchymal lung disease Year: 2010
Elevated circulating concentrations of adiponectin in sarcoidosis – a new marker of disease? Source: Annual Congress 2006 - Clinical features and disease markers of sarcoidosis Year: 2006
Serum markers of acute sarcoidosis. Source: Virtual Congress 2020 – Genetics and biomarkers for diagnosis and prognosis of granulomatous lung diseases Year: 2020
Serum cytokine and antiviral antibody in the clinical course of sarcoidosis Source: Eur Respir J 2003; 22: Suppl. 45, 46s Year: 2003
Is there any clinical application for determining the serum cytokines profile in sarcoid patients? Source: Annual Congress 2008 - Clinical aspects in the management of sarcoidosis Year: 2008
The evaluation of serum biomarkers in patients with sarcoidosis: Can visfatin be a new biomarker for sarcoidosis? Source: International Congress 2017 – Rare diseases Year: 2017
Interleukin-2 and C-reactive protein in assessing the effectiveness of pulmonary sarcoidosis treatment Source: International Congress 2017 – The many faces of sarcoidosis Year: 2017
Serum levels of IL-10 and IL-12 i patients with pulmonary sarcoidosis Source: Annual Congress 2009 - Inflammation and airways Year: 2009
Usefulness of serum procalcitonin levels in pulmonary tuberculosis Source: Eur Respir J 2011; 37: 371 Year: 2011
Cross-sectional and longitudinal measurement of autoantibody levels against GM-CSF is useful for predicting clinical courses of in autoimmune pulmonary alveolar proteinosis. Source: International Congress 2017 – Rare diseases Year: 2017
The diagnostic value of serum soluble CD 14 and IL-10 levels in newly diagnosed pulmonary tuberculosis patients and the relationship with disease extensity Source: Annual Congress 2013 –Diagnostic features of tuberculosis I Year: 2013
Usefulness of inflammatory markers: procalcitonin, neopterin, C-reactive protein and MR-proANP in the follow-up of patients with chronic obstructive pulmonary disease Source: Annual Congress 2008 - Biomarkers and antibiotic treatment of exacerbations of COPD Year: 2008
Human β-defensin 2 and interleukin-8 as potential serum markers of pulmonary emphysema Source: Annual Congress 2010 - COPD: systemic inflammation and comorbidities Year: 2010
TNF-a and IL-10 control macrophage expression of CXCL13, a prognostic biomarker of idiopathic pulmonary fibrosis Source: International Congress 2018 – Back to basics and translational research in idiopathic interstitial pneumonias Year: 2018
Angiogenic activity of sera from tuberculosis and sarcoidosis patients in relation to IL-12 and TNFα serum level Source: Annual Congress 2003 - Genetics and immunobiology of tuberculosis Year: 2003
IL-6 and IL-8 in stable and exacerbated IPF patients and their association to outcome Source: International Congress 2016 – ILD: from the bench to the bedside Year: 2016
Relationship between macrophage inflammatory protein-3β(MIP-3β) levels and clinical course of sarcoidosis Source: Eur Respir J 2002; 20: Suppl. 38, 173s Year: 2002